SCHEMBL4055397

SCHEMBL4055397

CCn1nc(-c2ccccc2)c(C(C)=O)c(Nc2cncc(C(=O)O)c2C)c1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 7/20 0.63
TP53 P04637 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
PDE4A P27815 4/20 0.41
PDE4C Q08493 4/20 0.41
PDE4D Q08499 4/20 0.41
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
CSF1R P07333 1/20 0.39
FGFR1 P11362 1/20 0.39
FLT1 P17948 1/20 0.39
KDR P35968 1/20 0.39
CSNK1A1 P48729 1/20 0.39
CDK8 P49336 1/20 0.39
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
CDK5 Q00535 1/20 0.39
PRKCQ Q04759 1/20 0.39
LRRK2 Q5S007 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4707690 0.86 PDE4B (0.70) PDE4BTP53SMN1; SMN2CSF1RFGFR1
SCHEMBL1652356 0.84 PDE4B (0.63) PDE4BTP53SMN1; SMN2PDE4APDE4C
SCHEMBL3022117 0.83 PDE4B (0.62) PDE4BTP53SMN1; SMN2CSF1RFGFR1
SCHEMBL4679348 0.83 PDE4B (0.67) PDE4BTP53SMN1; SMN2PDE4APDE4C
SCHEMBL4705603 0.83 PDE4B (0.69) PDE4BTP53SMN1; SMN2PDE4APDE4C
SCHEMBL4706572 0.82 PDE4B (0.66) PDE4BTP53SMN1; SMN2CSF1RFGFR1
SCHEMBL3032326 0.82 PDE4B (0.58) PDE4BTP53SMN1; SMN2PDE4APDE4C
SCHEMBL4706076 0.82 PDE4B (0.65) PDE4BTP53SMN1; SMN2PDE4APDE4C
SCHEMBL4708171 0.82 PDE4B (0.64) PDE4BTP53SMN1; SMN2CSF1RFGFR1
SCHEMBL1653257 0.81 PDE4B (0.66) PDE4BSMN1; SMN2ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491722-B2 Pyridazin-3(2H)-one derivatives LABORATORIOS ALMIRALL S.A. (ES) 2009-02-17 US disclosed
US-20060173008-A1 New pyridazin-3(2h)-one derivatives LABORATORIOS ALMIRALL, S.A. (ES) 2006-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173008-A1 New pyridazin-3(2h)-one derivatives PDE3A, PDE4A, PDE3B PDE4B 4/4885TP53 4770/4885SMN1; SMN2 3892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.